| abstract |
The compounds of formula (I) are inhibitors of HSP90 and are useful, for example, in the treatment of cancer: Formula (I) wherein R 2 is of formula (IA): -(Ar 1 ) m- (Alk 1 ) p- (Z) r- (Alk 2 ) s -Q (IA) Wherein, in any possible combination, Ar 1 is an optionally substituted aryl or heteroaryl group, and Alk 1 and Alk 2 are optionally substituted divalent C 1 -C a 3 alkylene or C 2 -C 3 alkenylene group, m, p, r and s are independently 0 or 1, Z is, -O -, - S -, - (C = O) -,-(C = S)-, -SO 2- , -C (= O) O-, -C (= O) NR A- , -C (= S) NR A- , -SO 2 NR A- , —NR A C (═O) —, —NR A SO 2 — or —NR A — (wherein R A is hydrogen or C 1 -C 6 alkyl) and Q is hydrogen or any A carbocyclic or heterocyclic group which may be substituted with R 3 is hydrogen, an optional substituent, or an optionally substituted (C 1 -C 6 ) alkyl, aryl or heteroaryl group; and R 4 is (i) hydrogen, -CN group, nitro group -NO 2 or -C (= NOH) (NH 2 ) group, or (ii) optionally substituted C 1 -C 6 alkyl, aryl, heterocyclic, aryl (C 1 -C 6 alkyl) - or a heterocyclic (C 1 -C 6 alkyl) - group, or (iii) formula -C (= O) R 5 (wherein, R 5 is hydroxyl, optionally substituted C 1 optionally -C 6 alkyl, C 1 -C 6 alkyloxy, aryl, aryloxy, heteroaryl, heteroaryloxy, aryl (C 1 -C 6 alkyl) -, Aryl (C 1 -C 6 alkoxy)-, heteroaryl (C 1 -C 6 alkyl)-, or heteroaryl (C 1 -C 6 alkoxy)-, or (iv) Formula -C (= O) NHR 6 ( In which R 6 is primary, secondary, tertiary or cyclic amino, or hydroxyl, optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkyloxy, aryl, Aryloxy, Heteroaryl, heteroaryloxy, aryl (C 1 -C 6 alkyl) -, aryl (C 1 -C 6 alkoxy) -, heteroaryl (C 1 -C 6 alkyl) -, or heteroaryl (C 1 -C 6 alkoxy )-). [Selection figure] None |